To order this
detailed 310+ page report, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Key Inclusions
§
A detailed assessment of the current market landscape of
therapeutics targeting STING pathway, based on several parameters, such as type
of STING modulator (agonist or antagonist), type of molecule (small molecules,
cyclic dinucleotides, non-nucleotides, biologics and others), phase of
development (discovery, preclinical and clinical), target therapeutic area(s),
type of therapy (monotherapy and combination therapy), route of administration
(intratumoral, intravenous and others), and line of treatment (last line,
second line or greater and first line or greater). The chapter also features an
analysis of the developer landscape (including information on year of
establishment, company size, geography and most active players). Further the
chapter includes an analysis on the clinical trials focused on STING, along
with information on parameters, such as recruitment status, study design and
clinical endpoints.
§
A detailed chapter highlighting various technology
platforms that are being actively used for the development of STING modulators
and analysis based on several parameters, such as type of modulator (agonist or
antagonist), type of molecule (small molecules, cyclic dinucleotides,
non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides),
and analysis based on technology developer landscape (including information on
year of establishment, company size and geography).
§
Elaborate profiles of key players that are engaged in the
development of therapeutics targeting STING pathway (shortlisted on the basis
of phase of development of pipeline products), featuring a brief overview of
the company, its financial information (if available), detailed descriptions of
their respective lead drug candidates, recent developments and an informed
future outlook. Additionally, each drug profile features information on the
type of drug, route of administration, target indications and current status of
development.
§
Tabulated profiles of industry players (shortlisted on the
basis of the antagonist in pipeline products), featuring details on the
innovator company (such as year of establishment, location of headquarters,
number of employees, key members of the executive team and recent
developments), along with descriptions of their respective drug candidates.
§
A study on various grants that have been awarded to
research institutes engaged in projects related to STING pathway, during the
period 2015 - Q1 2020, based on multiple parameters, such as number of grants
awarded, amount awarded, funding institute, support period, funding mechanism,
type of grant application, grant activity code, most popular NIH department,
type of recipient organization, regional distribution, most popular recipient
organization(s), prominent project leader(s) and study section. It also
includes an analysis of on grant attractiveness.
§
An analysis of big pharma players engaged in the
development of therapeutics targeting STING pathway, based on several
parameters, such as portfolio diversity, type of molecule, phase of
development, therapeutic area(s), type of therapy and route of administration.
In addition, the chapter features a benchmarking analysis of the aforementioned
players.
§
An analysis of the start-ups / small players (established
in the last ten years, less than 50 employees) engaged in the development of
therapeutics targeting STING pathway, based on several relevant parameters,
such as portfolio diversity, type of molecule, phase of development,
therapeutic area, funding received, number of investors, type of funding,
partnership activity, number of patents filed, grants received, and start-up
health indexing.
§
A detailed publication analysis of more than 300
peer-reviewed, scientific articles that have been published during the period
2019 - Q1 2020, highlighting the research focus within the industry. It also
highlights the key trends observed across publications, including information
on type of publication, year of publication, study objective, popular keywords,
type of STING modulator, target pathway, therapeutic area, type of publisher,
leading players (in terms of number of publications), region, first author
organization and key journals (in terms of number of articles published in this
domain).
§
An analysis of the partnerships that have been established
in the domain, over the period 2015 - Q1 2020, covering research agreements,
product / technology licensing agreements, mergers / acquisitions, R&D and commercialization agreements, IP
licensing agreements, clinical trial agreements, product development
agreements, and other relevant deals. The chapter highlights analysis based on
year of partnerships, type of partnership model, type of STING modulator,
therapeutic area, technology platform, most active player(s) (in terms of
number of partnerships inked), and region.
§
An analysis of the investments made at various stages of
development, such as seed financing, venture capital financing, debt financing,
grants / awards, capital raised from IPOs and subsequent offerings, by
companies engaged in this field. The chapter highlights analysis based on the
number of funding instances, amount invested, type of funding, type of STING
modulator, therapeutic area, technology platform, most active player(s) (in
terms of number of funding instances), most active investor(s) (in terms of
number of funding instances) and geographical region.
The report also features the
likely distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§
Types of Payment
§
Upfront Payments
§
Milestone Payments
§
Type of STING
Modulator
§
Agonist
§
Antagonist
§
Key Therapeutic
Area(s)
§
Oncological Disorders
§
Inflammatory
Disorders
§
Infectious Diseases
§
Others
§
Route of Administration
§
Intratumoral
§
Intravenous
§
Oral
§
Subcutaneous
§
Others
§
Type of Molecule
§
Non-nucleotide
§
Cyclic Dinucleotide
§
Live Biotherapeutics
§
Oncolytic Peptides
§
Synthetic Peptides
§
Others
§
Key Geographical
Regions
§
North America
§
Europe
§
Asia-Pacific
To request sample
pages, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market/request-sample.html
Key Questions Answered
§ Who are
the leading developers of STING pathway targeting therapeutics and affiliated
technologies?
§ What are
the most popular STING pathway related technology platforms in the market?
§ What are
the key therapeutic areas for which STING pathway targeting therapeutics are
being / have been developed?
§ What kind
of partnership models are commonly adopted by stakeholders engaged in this
industry?
§ What is
the trend of capital investment for STING pathway targeting therapeutics and
technologies?
§
How is the current and future opportunity likely to be
distributed across key market segments in this domain?
You may also be interested in the following
titles:
1. Nuclear Medicine and
Radiopharmaceuticals Manufacturing Market, 2020-2030
2. Global
Psychedelic Therapeutics Market by Type of Psychedelic Substance
(Ketamine, Psilocybin, MDMA and Others), by Origin (Natural and Synthetic), by
Type of Therapy (Monotherapy, Combination and Others), by Route of
Administration (Oral, Intravenous, Intranasal and Others) and by Key
Geographies (North America, Europe and Asia- Pacific and rest of the world):
Industry Trends and Global Forecasts, 2020-2030
3. Endocannabinoid
System Targeted Therapeutics Market, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
